1 GWAS of ~30,000 samples with bone mineral density

2 at multiple skeletal sites and its clinical relevance on

- 3 fracture prediction, genetic correlations and
- 4 prioritization of drug targets
- 5

6	Yu Qian ^{1,2,3}	[#] , Jiangwei Xia ⁴	[#] , Pingyu	Wang ^{5#} ,	Chao Xi	e ⁶ , Hong-Li	Lin ⁷ , Gloria Hoi-
---	--------------------------	--	-----------------------	----------------------	---------	--------------------------	--------------------------------

- 7 Yee Li⁸, Cheng-Da Yuan⁹, Mo-Chang Qiu¹⁰, Yi-Hu Fang¹⁰, Chun-Fu Yu¹¹, Xiang-
- 8 Chun Cai¹¹, Saber Khederzadeh^{1,2,3}, Pian-Pian Zhao^{1,2,3}, Meng-Yuan Yang^{1,2,3}, Jia-
- 9 Dong Zhong^{1,2,3}, Xin Li^{1,2,3}, Peng-Lin Guan^{1,2,3}, Jia-Xuan Gu^{1,2,3}, Si-Rui Gai^{1,2,3},
- 10 Xiang-Jiao Yi^{1,2,3}, Jian-Guo Tao^{1,2,3}, Xiang Chen^{1,2,3}, Mao-Mao Miao^{1,2,3}, Guo-Bo
- 11 Chen¹², Lin Xu⁵, Shu-Yang Xie⁵, Geng Tian⁵, Hua Yue¹³, Guangfei Li¹⁴, Wenjin
- 12 Xiao¹⁴, David Karasik¹⁵, Youjia Xu¹⁴, Liu Yang¹⁶, Ching-Lung Cheung¹⁷, Fei
- 13 Huang⁵, Zhenlin Zhang¹³, Hou-Feng Zheng^{1,2,3*}
- 14
- ¹The affiliated Hangzhou first people's hospital, School of Medicine, Westlake
- 16 University, Hangzhou, Zhejiang, China
- ²Diseases & Population (DaP) Geninfo Lab, Westlake Laboratory of Life Sciences
- 18 and Biomedicine, Hangzhou, Zhejiang, China
- ³ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, China;
- 20 ⁴Department of Neurology, Xuanwu Hospital, National Center for Neurological
- 21 Disorders, Capital Medical University, Beijing, China

- ⁵WBBC Shandong Center, Binzhou Medical University, Yantai, Shandong, China
- 2 ⁶Institute of Science and Technology for Brain-Inspired Intelligence, Fudan
- 3 University, Shanghai, China
- ⁴ ⁷School of Public Health, The University of Hong Kong, Pok Fu Lam, Hong Kong
- 5 SAR, China.
- ⁸Department of Health Technology and Informatics, Faculty of Health and Social
- 7 Sciences, The Hong Kong Polytechnic University, Hong Kong, China.
- 8 ⁹Department of Dermatology, Hangzhou Hospital of Traditional Chinese Medicine,
- 9 Hangzhou, Zhejiang, China
- 10 ¹⁰WBBC Jiangxi Center, Jiangxi Medical College, Shangrao, Jiangxi, China
- 11 ¹¹Department of Orthopedic Surgery, Shangrao Municipal Hospital, Shangrao,
- 12 Jiangxi, China
- 13 ¹²Clinical Research Institute, Zhejiang Provincial People's Hospital, People's
- 14 Hospital of Hangzhou Medical College, Hangzhou, China
- ¹³Department of Osteoporosis and Bone Disease, Shanghai JiaoTong University
- 16 Affiliated Six People's Hospital, Shanghai, China.
- ¹⁴Department of Orthopaedics, Second Affiliated Hospital of Soochow University,
- 18 Osteoporosis Research Institute of Soochow University, Suzhou, Jiangsu, China.
- ¹⁵Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel
- 20 ¹⁶Institute of Orthopedic Surgery, Xijing Hospital, Fourth Military Medical
- 21 University, Xi'an, Shaanxi, China

- 1 ¹⁷Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine,
- 2 The University of Hong Kong, Hong Kong, China.
- 3
- 4 #These authors contributed equally
- 5 *Correspondence: zhenghoufeng@westlake.edu.cn (H.-F.Z.)
- 6
- 7

1 Abstract

2 We conducted genome-wide association studies (GWAS) of dual-energy X-ray 3 absorptiometry (DXA)-derived bone mineral density (BMD) traits at 11 skeletal 4 sites, within over 30,000 European individuals from the UK Biobank. A total of 92 5 unique and independent loci were identified for 11 DXA-derived BMD traits and 6 fracture, including five novel loci (harboring genes such as ABCA1, CHSY1, 7 CYP24A1, SWAP70, and PAX1) for six BMD traits. These loci exhibited evidence of 8 association in both males and females, which could serve as independent replication. 9 We demonstrated that polygenic risk scores (PRSs) were independently associated 10 with fracture risk. Although incorporating multiple PRSs (metaPRS) with the 11 clinical risk factors (i.e., the FRAX model) exhibited the highest predictive 12 performance, the improvement was marginal in fracture prediction. The metaPRS 13 were capable of stratifying individuals into different trajectories of fracture risk, but 14 clinical risk factors played a more significant role in the stratification. Additionally, 15 we uncovered genetic correlation and shared polygenicity between head BMD and 16 intracranial aneurysm. Finally, by integrating gene expression and GWAS datasets, 17 we prioritized genes (e.g. ESR1 and SREBF1) encoding druggable human proteins 18 along with their respective inhibitors/antagonists. In conclusion, this comprehensive 19 investigation revealed a new genetic basis for BMD and its clinical relevance on 20 fracture prediction. More importantly, it was suggested that head BMD was 21 genetically correlated with intracranial aneurysm. The prioritization of genetically 22 supported targets implied the potential repurposing drugs (e.g. the n-3 PUFA 23 supplement targeting SREBF1) for the prevention of osteoporosis.

24

Keywords: bone mineral density, drug targets, fracture, genome-wide association
study, intracranial aneurysm, omics, polygenic risk scores.

1 Introduction

2 Osteoporosis, a systemic skeletal disease characterized by decreased bone mass and micro-structural damage^{1,2}, has a global prevalence of 18.3% [95% confidence 3 interval (95% CI): 16.2%-20.7%]³. Bone mass could be assessed by 2-dimensional 4 5 projectional scans with dual-energy X-ray absorptiometry (DXA), or other medical 6 imaging tools, such as quantitative computed tomography (QCT) and quantitative ultrasound (QUS)⁴. Genome-wide association studies (GWASs) and meta-analyses 7 8 were carried out to explore the genetic factors for bone mineral density (BMD), 9 osteoporosis, and fracture ^{1,2}. Early GWAS design only involved thousands of samples and only several loci were identified ^{5,6}. The meta-analysis could enlarge 10 the sample size and statistical power, and lead to the identification of more loci 7,8 . 11 12 However, the genetic summary data, instead of individual-level genotype data, from 13 each cohort were meta-analyzed in the aforementioned studies. Recently, large-scale 14 biobanks such as the UK biobank could enable access to the individual-level 15 genotype data in hundreds of thousands of samples, and hundreds of genetic loci were identified for OUS-derived BMD in these efforts ^{9,10}. 16

17

18 Although GWASs have been successfully conducted in the past decade, the ultimate 19 goal of genetic study is to translate the discoveries into clinical practice. Previously, 20 we have tried to summarize the clinical use of GWAS findings in the bone field, 21 such as disease prediction¹. Lu et al developed the genetically predicted speed of 22 sound (SOS, a parameter measured by QUS) for individuals in UK Biobank by 23 common genetic variants through polygenic risk score (PRS)¹¹. They demonstrated 24 that this score provided modestly better fracture risk prediction than some of the 25 clinical risk factors such as smoking and use of corticosteroids ¹¹. In addition, they 26 suggested that adding rare variants did not demonstrate substantially improved predictive performance in a recent study ¹². The above studies took the SOS 27 28 measurement in the training and testing dataset, however, the SOS measurement was

not correlated very well with BMD ¹³. Another clinical relevance of GWAS findings is to infer the correlation between diseases ¹. Earlier efforts have uncovered numerous SNPs exhibiting pleiotropic associations with BMD and other traits/diseases, such as birth weight ¹⁴, type 2 diabetes ¹⁵, and major depressive disorder ¹⁶. Finally, incorporating genetic data in drug development is warranted to improve this process, because drugs with genetic support are more likely to succeed in clinical trials ^{17,18}.

8

9 Therefore, with the availability of DXA-derived BMD phenotypes and individual-10 level genotype data in UK Biobank, it is an opportunity to conduct a genome-wide 11 association study at large scale individual-level genotype data and to investigate the 12 genetic basis of BMD at 11 sites (arm, femur total, femur neck, head, leg, pelvis, 13 lumbar spine, rib, and spine) and fracture (Supplementary Figure 1). We then build 14 a 'multi-BMD PRS' predictive model to improve genetic risk stratification for 15 fracture. In addition, we estimated the shared genetic architecture of BMD with 16 other common chronic diseases, including neurodegenerative, cardiovascular, and 17 autoimmune diseases. Finally, we tried to explore the potential effective and safe 18 therapeutic targets for osteoporosis.

19

20 **Results**

21 Genetic architecture of BMD at multiple skeletal sites

The overview of the study design was presented in Supplementary Figure 1.
Specifically, we conducted the GWAS analyses for BMD at 11 anatomic sites (i.e., arm, total femur, femoral neck, head, legs, lumbar spine, pelvis, ribs, spine, trunk, and total body) and any-type fracture (Figure 1A) in male and female separately.
For each BMD trait, we then conducted meta-analyses to combine the results from both genders (for BMD traits: N≈30,000; for any-type fracture: N=35,192 for cases; N=317,599 for controls). The reported loci should exhibit evidence of association in

1 both males and females, which could serve as independent replication (Figure 2 A-E 2 **Supplementary Table 1,** and **Supplementary Table 2**). All intercept values from 3 the LD score method were close to one, revealing no obvious population 4 stratification for all GWASs (Supplementary Table 3). We observed that 5 approximately 25.7%~41.8% of the variance in BMD and 4.8% of the variance in 6 fracture risk could be explained by common variants across the genome (**Table 1**). 7 We then conducted conditional analyses within phenotype and identified 240 unique 8 conditional independent BMD signals (Table 1, Figure 1B, Supplementary Table 1, 9 and **Supplementary Figure 2-13**). After merging the physically overlapped signals 10 across BMD phenotypes (i.e., the distance between two conditional independent 11 SNVs < 500kb) into one locus, a total of 91 unique and independent BMD loci were 12 defined (Table 1, Figure 1B and Supplementary Table 1). We identified 8 loci for 13 fracture, 7 of which overlapped with the above BMD signals, and one of which 14 (independent SNP: rs13281992) was previously reported to be genome-wide significant associated with heel BMD¹⁰ (Table 1, Figure 1B and Supplementary 15 16 Table 1).

17

18 *Five loci identified for DXA-derived BMD traits*

19 Although previous GWASs have reported hundreds of loci, we still identified five 20 loci for six BMD traits that were not reported previously (Figure 1B and Figure 2 21 **A-E**). Among these loci, the most pleiotropic locus resided between *ABCA1* and 22 SLC44A1 genes on chromosome 9 (Figure 1B, Figure 2A, and Supplementary 23 Table 4). SNPs (rs1039406 and rs746100) around this locus were genome-wide 24 significantly associated with five BMD sites, including the lumbar spine, femur neck, 25 femur total, pelvis, and trunk (Figure 1B, Figure 2A, and Supplementary Table 1). 26 The eQTL data from whole blood tissue revealed that SNP rs746100 was also associated with the gene expression of ABCA1 ($P=2.68\times10^{-5}$) in artery tibial tissue, 27 28 based on the GTEx consortium (Supplementary Table 5 and Supplementary

1 Figure 14), and the genetically predicted higher ABCA1 gene expression in whole 2 blood tissue was associated with higher BMD (Figure 2A). The second promising 3 locus resided between SWAP70 and WEE1 genes on chromosome 11 with leading 4 SNP rs10840273, showing a genome-wide significant association for leg BMD (Pvalue=4.52×10⁻⁹) (Figure 2B, Supplementary Table 1 and Supplementary Table 5 6 4). Whole blood eQTL data from eQTLGen identified that rs10840273 was associated with the SWAP70 gene expression ($P=2.42\times10^{-39}$) (Supplementary 7 8 Table 5 and Supplementary Figure 15). Mesenchymal stem cell Hi-C data also 9 detected a direct interaction of the associated region with the SWAP70 gene (FDRcorrected *P*-value_{interaction}= 2.74×10^{-109}) (Supplementary Table 6). Furthermore, this 10 11 lead SNP showed a genome-wide significant association with circulating SWAP70 $(P-value=6.94\times10^{-81})$. The MR results revealed that genetically predicted higher 12 SWAP70 gene expression and higher circulating SWAP70 protein in whole blood 13 14 were significantly associated with increased leg BMD (Figure 2B).

15

16 Another locus surrounding rs12916774 on chromosome 15 was associated with 17 femur neck and femur total BMD (Figure 2C and Supplementary Figure 16). Both 18 eQTL data and Mesenchymal stem cell Hi-C data consistently supported the CHSY1 as a plausible candidate gene ($P=2.15\times10^{-53}$ for CHSY1 eQTL in whole blood tissue 19 20 FDR-corrected $P_{\text{interaction}} = 1.72 \times 10^{-49}$ eQTLGen: for Hi-C from data) 21 (Supplementary Table 5 and Supplementary Table 6). The fourth locus (lead 22 SNP: rs6013897) was an intergenic region of CYP24A1 and BCAS1 (Figure 2D, 23 Supplementary Table 4 and Supplementary Figure 17). The Mesenchymal stem 24 cell Hi-C data detected a direct interaction of the associated region with the CYP24A1 gene (FDR-corrected $P_{\text{interaction}} = 8.04 \times 10^{-78}$) (Supplementary Table 6). 25 26 We further prioritized PAX1 as a potential candidate gene for rs927059, which is a 27 lead SNP for femur neck BMD (*P*-value= 1.87×10^{-8}) (Figure 2E, Supplementary 28 Table 4 and Supplementary Figure 18). The positional and eQTL annotation results consistently supported the *PAX1* as a candidate gene for rs927059 (*P*-value=4.40×10⁻⁶ for *PAX1* eQTL in muscle skeletal tissue from GTEx)
(Supplementary Table 4 and Supplementary Table 5). In summary, using multi-omics datasets, we prioritized 5 potential candidate genes (i.e., *ABCA1*, *CHSY1*, *CYP24A1*, *SWAP70*, and *PAX1*) to 5 novel loci (Figure 1B, Figure 2 A-E, and
Supplementary Table 4-6). The annotation results for other known loci have also been shown in Supplementary Table 4-7.

8

9 Polygenic risk score demonstrated marginal improvement in

10 **fracture prediction**

11 Based on effect size derived from GWASs 11 DXA-BMD traits, heel BMD, and 12 fracture in training datasets, we selected SNPs that could achieve the best predictive 13 PRSs for fracture in the validation dataset (Figure 3A), resulting in 29 (for rib 14 BMD)-79292 (for head BMD) selected SNPs for different trait (Supplementary 15 **Table 8**). After obtaining SNPs and the effect size for each trait, we calculated the 16 corresponding PRS for each participant in the test dataset (Figure 3A). The 17 metaPRS was generated by integrating these 13 individual PRSs using stepwise Cox 18 regression in the validation cohort dataset (Figure 3A), with estimates for each 19 single PRS contained in the best-performing model (Supplementary Table 9). The 20 association of metaPRS with fracture incidence was largely independent of the 21 traditional risk factors (Supplementary Table 10). As illustrated in Figure 3B, 22 most individual PRSs showed significant associations with fracture risk in the test 23 cohort dataset ($P \square < 0.05$) after adjusting for age, sex, obesity, smoking, alcohol, 24 glucocorticoid medicine use, BMD, and population stratification. However, these 25 PRSs exhibited similar effect estimates for fracture risk, with the metaPRS 26 displaying the most prominent association [HR: 1.134, 95% confidence interval (CI) 1.098-1.172, $P \square = \square 4.15 \times 10^{-14}$] (Figure 3B). Furthermore, we observed a more 27 28 marked gradient of fracture risk across quintiles of metaPRS (HR=1.364, 95%

CI=1.243-1.498) than fracture PRS (HR=1.177, 95% CI=1.077-1.287) in the top
 quartile vs. the bottom quartile (Supplementary Table 11).

3

4 By including only clinical factors such as age, sex, BMI, smoking, alcohol use, and 5 glucocorticoid use (the FRAX model), we observed limited predictive performance 6 of this model (C-statistic=0.608, sd=0.005) (Figure 3C and Supplementary Table 7 12). We found that adding BMD to the FRAX model increased the C-statistic from 0.608 to 0.637 (difference, 4.77%, $P=3.77\times10^{-21}$) (Figure 3C and Supplementary 8 9 Table 12). However, the addition of various PRS to the FRAX-BMD model did not 10 substantially improve the C-statistic (Figure 3C and Supplementary Table 12). 11 Incorporating metaPRS into the FRAX-BMD model resulted in the highest C-12 statistic (C-statistics = 0.641), with a C-statistic change of 0.63% (P=0.003), 13 compared with the FRAX-BMD model (Figure 3C and Supplementary Table 12). 14 By utilizing the optimal cutoff point from the FRAX-BMD metaPRS model as the 15 threshold, the combination of metaPRS and FRAX-BMD model yielded a moderate 16 improvement in net reclassification improvement (NRI=1.66%, 95% CI 0.7%-2.62%; 17 the continuous NRI: 9.15%, 95% CI 6.39%-11.91%) (Supplementary Table 13).

18

19 We further assessed how the interplay of the metaPRS and clinical risk factors 20 impact the fracture risk. Firstly, we found that the cumulative incidence for fracture 21 events was 4.63% for individuals with low polygenic risk (bottom quintiles of the 22 metaPRS) and 7.58% among those with high polygenic risk (top quintiles of the 23 metaPRS), suggesting that metaPRS could stratify individuals into different 24 trajectories of fracture risk (Supplementary Figure 19). Similar results were 25 observed in both sexes, with women having higher HR (Supplementary Table 11) 26 and higher cumulative risk (Supplementary Figure 20 and Supplementary Figure 27 21). Although we observed significant gradients in the 10-year probability of 28 fracture occurrence across metaPRS categories within each clinical risk strata

1 (Figure 3D), the clinical risk factors played more important role in the stratification. 2 For example, among participants with low clinical risk, the 10-year probability of 3 fracture occurrence for those with high genetic risk (2.40% sd=0.59%) was yet 4 lower than the participants with median clinical risk but low genetic risk (3.26%, 5 sd=0.69%) (Figure 3D). And the 10-year probability of fracture of the participants 6 at high clinical risk with low genetic risk (5.81%, sd=1.27%) had already exceeded 7 the 10-year probability in fracture cases only (5.35%, sd=2.63%) (Figure 3D). The 8 lifetime risk of incident fracture was higher in each stratum than the 10-year 9 probability (Figure 3D). Participants at high clinical risk with median/high genetic 10 risk demonstrated lifetime probabilities of 10.18% and 12.08%, surpassing the 11 intervention treatment threshold of 10% for a major fracture at age 55 years when treatment should be recommended ¹⁹(Figure 3D). 12

13

14 The shared genetic architecture of head BMD and intracranial

15 aneurysm

16 We further estimated the shared genetic architecture of DXA-BMD at 11 sites with 17 other 13 common chronic diseases, including neurodegenerative diseases, 18 cardiovascular diseases and autoimmune diseases (Supplementary Table 14). First 19 of all, we tested the pair-wise correlation between the BMD traits. It is suggested 20 that there were the weakest correlations for head BMD with other BMD traits in 21 both phenotypic and genetic correlation analyses, although all pairs exhibited 22 statistically significant phenotypic correlation (Figure 4A). In the 143 BMD-disease 23 pairs (11 BMD traits \times 13 diseases), we only observed a statistically significant 24 inverse genetic correlation of head BMD with intracranial aneurysm (IA) (rg=-0.188, 25 se=0.055, FDR-corrected P=0.0096), while the genetic correlations with other 12 26 common chronic diseases were not significant (FDR-corrected P>0.05) (Figure 4B 27 and Supplementary Table 14). Furthermore, no significant genetic correlation was 28 observed for the remaining 10 DXA-BMD traits with IA (FDR-corrected P>0.05)

1 (Figure 4B and Supplementary Table 14). Compared to the specificity of observed 2 genetic correlation, there was a similar MiXeR estimated polygenic overlap between 3 head BMD and IA. 29.36% (N=114, SD=15) of the 390 head-BMD influencing 4 variants were also predicted to influence IA (Figure 4C and Supplementary Table 5 **15**). By employing the conjFDR method, we identified four genomic loci jointly 6 associated with head BMD and IA (Figure 4D, Figure 4E, and Supplementary 7 **Table 16**). Intriguingly, 3 of the 4 lead SNPs (rs72560793, rs10958404, rs11187838) 8 had the opposite effect direction, consistent with the moderate inverse genetic 9 correlation between head BMD and IA (Figure 4E, and Supplementary Table 16). 10 Notably, two of the four loci demonstrated strong evidence of colocalization 11 (H4>0.5), suggesting the presence of shared causal variants between head BMD and 12 IA (H4: 0.809 for rs10832558 within SOX6; H4: 0.581 for rs11187838 within 13 *PLCE1*) (Supplementary Table 17). Genes mapped to these shared loci were 14 enriched for biological processes and cellular components related to the skeletal 15 systems (e.g., positive regulation of chondrocyte differentiation) and vascular 16 smooth muscle (i.e., regulation of Ras protein signal transduction) (Supplementary 17 **Table 18**).

18

19 Prioritization of drug targets

20 Subsequently, by integrating the druggable genome, gene expression, and GWAS 21 datasets, we aimed to identify the genetically supported potential therapeutic targets 22 for osteoporosis, emulating exposure to corresponding medications. Utilizing drug 23 target information from the ChEMBL database (release 29), we included a total of 24 3,329 druggable genes for subsequent analyses. Next, we employed eQTL data from 25 muscle (including 791 druggable genes), artery tibial (917 druggable genes), and 26 whole-blood tissue (845 druggable genes from GTEx; 2104 druggable genes from 27 eQTLGen) to test the association with BMD through mendelian randomization 28 approach. We observed statistically significant associations between genetically

1 predicted expression of 15 genes and DXA-BMD (FDR-corrected P < 0.05) 2 (Supplementary Table 19). Among these, genetically predicted expressions of 4 3 genes (CCR1, ESR1, NCOR1 and SREBF1) were associated with at least two DXA-4 BMD traits with consistent direction, providing robust MR evidence for the genes 5 (Figure 5A, 5B and Supplementary Table 19). For these four genes, genetically 6 predicted ESR1 gene expression showed negative associations with 9 DXA-BMD 7 traits (Figure 5A and 5B). There were positive associations of genetically predicted 8 NCOR1 gene expression with head BMD and total BMD, while negative 9 associations were found for SREBF1 and CCR1 gene expressions (Figure 5A and 10 **5B**). To assess whether the genetic association between these gene expressions and 11 phenotypes shared the same causal variant, we conducted colocalization analyses of 12 the genes with DXA-BMD traits. We discovered that eQTLs in whole blood tissue 13 for 3 genes (i.e., SREBF1, NCOR1 and CCR1) colocalized with DXA-BMD loci 14 (H4>0.5), reinforcing the evidence for these genes as drug targets for DXA-BMD 15 (Figure 5C and Supplementary Table 20). Considering the observed negative 16 between SEEBF1 and CCR1 association gene expression and BMD 17 (Supplementary Table 19), there were relevant inhibitors/antagonists that have 18 been approved or under investigation that present possible repurposing opportunities 19 for osteoporosis treatment. Specifically, SEBF1 could be targeted using Doconexent 20 (inhibitor) and Omega-3 fatty acids (inhibitor), while CCR1 could be targeted using 21 CCX354-C (antagonist) (Figure 5D).

22

23 **Discussion**

In this study, we first conducted the large-scale GWASs of DXA-BMD at 11 skeletal sites, and identified 91 unique and independent loci associated with at least one phenotype, including five previously unreported BMD loci for six BMD traits (i.e., *ABCA1*, *CHSY1*, *CYP24A1*, *SWAP70* and *PAX1*). These novel loci exhibited evidence of association in both male and female, which could serve as indepdent

1 replication. Additionally, the incorporation of multiple PRSs (metaPRS) with the 2 clinical risk factors (i.e., the FRAX model) exhibited the highest predictive 3 performance, however, the improvement was marginal in fracture prediction. 4 Although the metaPRS could stratify individuals into different trajectories of 5 fracture risk, the clinical risk factors played a more important role in the 6 stratification. We further estimated the shared genetic architecture of DXA-BMD at 7 11 sites with other common chronic diseases, including neurodegenerative diseases, 8 cardiovascular diseases and autoimmune diseases, and we only uncovered genetic 9 correlation and shared polygenicity between head BMD and intracranial aneurysm. 10 And the gene *PLCE1* might play important roles in the shared polygenicity. Finally, 11 by integrating the gene expression and GWAS datasets, we prioritized drug targets 12 (e.g. *ESR1*, *SREBF1*, *CCR1* and *NCOR1*) within the druggable genomic genes along 13 with their respective inhibitors/antagonists.

14

Although previous GWAS have identified hundreds of association signals ^{1,2}, we 15 16 considered reporting five loci in this study when the associated SNPs improved at 17 least two orders of magnitude of significance compared to the most significant SNPs 18 within the region (position-of-reported-SNP±250 kb) in any of the previous BMD 19 GWASs. For example, in our study, the locus (rs746100) near ABCA1 was 20 associated with five BMD traits, including the lumbar spine, femur neck, total femur, 21 pelvis, and trunk with the smallest P-value at 1.64×10^{-9} . By looking back at the 22 meta-analysis of GWAS in a relatively large sample size (N = ~30,000), the SNP 23 rs1831554 within this locus had a marginal significance for femur neck ($P=9.94\times10^{-1}$ 24 ⁵) and lumbar spine ($P=1.41\times10^{-4}$) BMD ⁸. The pair-wise LD of the two lead SNPs 25 was 0.0005. In our study, we used the individual-level genotype data within \sim 30,000 26 samples, the sample size was as large as the GWAS meta-anlaysis of summary 27 statistic data⁸, but the association significance improved greatly. It is suggested that 28 the association analysis performed in individual-level genotype data could enable a

1 more comprehensive power to control various factors, such as population structure, covariates, and phenotype definitions ²⁰. Another example was the locus near the 2 CHSY1 gene, this locus showed marginal significance (P-value= 2.30×10^{5} for 3 rs3784491) in the largest-scale GWAS to date for QUS-derived heel BMD¹⁰, the 4 5 sample size was more than ten times compared to our study, however, the SNP 6 rs12916774, with very low LD with rs3784491 (LD $r^2=0.005$), was found to be 7 genome-wide significantly associated with femur neck BMD in our study $(P=2.14\times10^{-9})$. It should be noted that QUS-derived BMD primarily reflected the 8 9 bone mass at the heel calcaneus and exhibited limited correlation $(0.5 \sim 0.65)$ with 10 DXA-derived BMD at the spine and hip ²¹. Additionally, we confirmed the ZIC1/ZIC4 locus for head BMD ($P=2.19\times10^{-8}$) which was reported in a very recent 11 12 GWAS meta-analysis²².

13

One of the potential applications of genetic data is disease prediction 1 . Lu et al 14 15 calculated the genetically predicted speed of sound (SOS, measured by quantitative 16 ultrasound at the heel) for individuals in the UK Biobank and assessed the predictive 17 performance of this score ¹¹. In this study, we used three independent datasets and 18 generated PRSs for the DXA-derived BMD at multiple skeleton sites. Our results 19 indicated that PRSs had robust associations with incident fracture, even after 20 adjusting for the related clinical risk factors such as age, sex, obesity, smoking, 21 alcohol, glucocorticoid use and BMD, suggesting the independent contribution to 22 the susceptibility of fracture. We further built metaPRS by combining multiple PRSs 23 for DXA-BMD, heel BMD, and fracture to evaluate the potential of PRSs on 24 fracture prediction. As expected, the metaPRS showed a larger effect size on 25 fracture risk than fracture PRS. This improvement could be attributed to that the 26 genetic component of this metaPRS captured the majority of the genetic basis of fracture. At baseline, we included the FRAX factors ²³ in the prediction model, and 27 only limited predictive performance was observed just as before ²⁴. We observed an 28

1 increased C-statistic when incorporating BMD into the FRAX model. However, the 2 addition of various PRS to the FRAX-BMD model did not substantially improve the 3 C-statistic, suggesting that the predictive performance of PRS did not perform as 4 well as BMD measurement itself. Additionally, the probability of fracture 5 occurrence for those with low clinical risk and high genetic risk was yet lower than 6 the participants with median clinical risk but low genetic risk, suggesting that the 7 clinical risk factors played a more important role in the stratification. Lu et al 8 suggested that the predictive performance of genetically determind SOS surpassed 9 single clinical risk factor such as smoking, corticosteroids use and falls etc¹¹, but 10 they did not test the combination of the these risk factors. Consistently, the predictive performance of PRS would not outperform BMD¹¹. 11

12

13 Clinically, intracranial aneurysm (IA) is characterized by a bulge or distention of an artery in the brain due to weakness and inelasticity of the vessel wall ²⁵. The 14 15 disruption of the extracellular matrix (ECM) has been proposed as a contributing factor in the pathophysiology of IA²⁶. The ECM is a also salient feature of bone 16 17 tissue. Bone ECM, containing minerals deposited on highly crosslinked collagen 18 fibrils, dynamically interacts with osteoblasts and osteoclasts to regulate the process of bone regeneration ²⁷. Given the shared histological basis of bone and vessel, the 19 20 genetic correlation analysis in this study suggested that higher head BMD would 21 associated with a lower risk of IA. This genetic association was supported by an 22 epidemiological study that the IA risk was increased in patients with BMD in middle 23 and lower tertiles compared with patients with BMD in higher tertile²⁸. Further, 24 with conditional false discovery rate approach ²⁹, we identified four shared signals, 25 emphasizing the pleiotropic effect underlying BMD and IA. Two of them 26 demonstrated evidence of colocalization (rs10832558 near SOX6 and rs11187838 27 near PLCE1). The SNP rs10832558 was at the same effect direction for head BMD 28 and IA, which was not consistent with the inverse genetic correlation. Here, we

1 highlighted the variant rs11187838 shared by BMD and IA with opposite effect 2 direction, which had not been detected by both previous single-trait analyses. This 3 SNP was mapped to the PLCE1 gene, encoding the enzyme phospholipase C 4 epsilon-1. This enzyme could stimulate the Ras and mitogen-activated protein 5 kinase (MAPK) signaling pathway through the regulation of heterotrimeric G 6 protein Galpha³⁰. Ras signaling stimulated the proliferation of immature 7 osteoprogenitor cells to increase the number of osteoblastic descendants in a cellautonomous fashion³¹. Additionally, the activation of Ras/MAPK signals could 8 9 stimulate the migration and proliferation of vascular smooth muscle cells through 10 fibronectin³². These synthetic vascular smooth muscle cells could secrete large 11 amounts of ECM components, including collagen, elastin, and matrix metalloproteinase, causing vascular ECM remodeling ³³. All these results suggested 12 13 that *PLCE1* might play important roles in the shared polygenicity between BMD and 14 IA. Finally, we did not observe genetic correlations between BMD and other 15 diseases in our study. As the global genetic correlation represented the average of 16 genome-wide shared association, the nonsignificant global correlation might be due 17 to opposing directions at different genomic regions 34 .

18

19 Several pharmacological agents were available to osteoporosis patients, either by 20 reducing bone resorption such as bisphosphonate and denosumab, or by stimulating 21 bone formation such as teriparatide and abaloparatide ³⁵. The fruitful GWAS 22 discoveries in the bone field have proven useful in identifying compounds suitable 23 for drug repurposing ³⁶. One possible approach is to use genetic variants associated 24 with the expression level of a gene encoding druggable human protein to proxy the lifelong exposure to a medication targeting corresponding gene production ^{37,38}. This 25 26 Mendelian randomization (MR) approach could mimic a randomized controlled trial 27 to cost-effectively predict the treatment response of a drug ^{37,38}. In this study, by using GWAS data and eQTL data, we prioritized several drug targets for 28

1 osteoporosis such as ESR1 and SREBF1, etc. The estrogen hormone therapy, 2 targeting ESR1 protein, was an old-fashioned treatment for osteoporosis and was 3 rarely used nowadays because of the adverse side effects such as cardiovascular conditions and cancer³⁹. The SREBF1 we would highlight here was the target of 4 5 Doconexent (a high-docosahexaenoic acid supplement) and Omega-3 fatty acids. 6 Daily marine $\text{omega} \square 3$ supplementation had been widely recommended in the prevention of adverse coronary events ^{40,41}. However, the effect of this kind of fatty 7 8 acid on bone health is controversial. For example, a meta-analysis of 23 randomized 9 controlled trials did not show any significant effect of n-3 PUFA supplementation on 10 BMD at any body's part ⁴². Nevertheless, when subgroup analyses were performed, 11 it was observed that the impact of n-3 PUFA supplementation on BMD varied across different regions ⁴². Specifically, individuals from Eastern countries exhibited 12 13 higher BMD at the lumbar spine and femoral neck following n-3 PUFA supplementation, in comparison to individuals from Western countries ⁴². However, 14 15 another systematic review and meta-analysis of randomized controlled trials 16 suggested that n-3 PUFAs might have a beneficial effect on bone health, especially 17 for postmenopausal women⁴³. In our study, we revealed a negative association 18 between SREBF1 gene expression and BMD. Previous studies suggested that the 19 supplement of omega-3 polyunsaturated fatty acid negatively regulated SREBF1 ^{44,45}. And decreased expression of the *SREBF1* gene could inhibit osteoclast 20 21 formation and bone resorption activity by decreasing NF-kB signaling ⁴⁶. Therefore, 22 we hypothesized that the n-3 PUFA supplementation might be effective for the 23 prevention of osteoporosis. For CCR1 antagonist, BMS-817399 failed in Phase 2, 24 double-blind, placebo-controlled clinical trial ⁴⁷, while another CCR1 antagonist 25 (CCX354-C) has shown a good safety and tolerability profile and evidence of clinical activity in rheumatoid arthritis in Phase II trials (NCT01242917)⁴⁸. Previous 26 27 animal study have shown that the activation of CCR1 leads to the formation of osteolytic lesions through the regulation of CCL3⁴⁹. 28

1

2 In conclusion, we conducted large-scale GWASs of DXA-derived BMD traits and 3 identified novel signals that will likely provide new insights into the biological 4 mechanism of osteoporosis. We demonstrated that although PRSs were 5 independently associated with fracture risk, the predictive performance improved 6 marginally compared to the clinical risk factors. Additionally, we uncovered a 7 genetic correlation between head BMD and IA, and the joint associated genes such 8 as PLCE1 might play important roles in the shared genetic basis. Finally, the 9 prioritization of genetically-supported targets implied the potential repurposing 10 drugs (for example the n-3 PUFA supplements targeting SREBF1) for the 11 prevention of osteoporosis.

1 Materials and methods

2 Source of the phenotypes and quality control of the genotype

As we used before ⁵⁰⁻⁵², the individual-level data from the UK biobank (Application 3 4 41376) was used for discovery analyses. The UK Biobank is a cohort of roughly 5 ~500,000 participants aged 40-69 years, of which, 487,409 participants were 6 genotyped with the UK Biobank Axiom or UK UKBiLEVE Array, and then imputed by the 1000 Genomes Project (Phase 3) reference panel ^{53,54}. Ethics 7 8 approval for the UK Biobank research was obtained from the North West 9 Multicentre Research Ethical Committee, and all participants provided informed 10 consent (original ethics committee approval number: 21/NW/0157). In this study, 11 we extracted BMD traits measured by dual-energy X-ray (DXA) from 11 anatomical 12 sites (i.e., arm, total femur, femoral neck, head, legs, lumbar spine, pelvis, ribs, spine, 13 trunk, and total body) and fracture as phenotypes (Figure 1A and Supplementary 14 Table 21). The fracture cases were defined as participants with the diagnosis of any 15 site of fracture (except fractures with known primary diseases and those with 16 diseases that might affect bone health) (Supplementary Table 21). To minimize the 17 population stratification bias, we further excluded participants who were not of 18 European ancestry (Supplementary Table 21), and those who had a kinship with 19 any participants. For quality control of genotype data, the variants were excluded if 20 the minor allele frequency (MAF) < 0.01, imputation info score < 0.3, missing genotype rates > 0.05, and *P*-value for Hardy–Weinberg equilibrium test $< 1 \times 10^{-6}$. 21 22 After the quality control, a total of 5,996,792 imputed variants and around ~30,000 23 participations (Figure 1A and Table 1) remained for BMD GWAS analysis, as well 24 as 352,791 participants (N=35,192 for cases; N=317,599 for controls) for fracture 25 GWAS (Figure 1A and Table 1).

1 Genetic association analysis of BMD and fracture

2 To identify the genetic variants associated with BMD at a genome-wide significant level ($P \le 5 \times 10^{-8}$), we conducted the GWAS analyses on BMD traits at 11 skeletal 3 sites. For BMD at each site, the values (g/cm^2) were stratified by sex, and then 4 adjusted for age, age², weight, menopause status (only for females), and first 5 5 6 principal components using linear regression. The standardized residuals (mean=0 7 and sd=1) in males and females (i.e., standardized BMD) were used in the GWAS 8 analyses. The associations between genetic variants with phenotypes (i.e., 9 standardized-BMD at 11 skeletal sites) were analyzed using the PLINK software 10 (http://www.cog-genomics.org/plink2/). We then combined the summary statistics 11 of the two sexes by an inverse variance weighted fixed effects meta-analysis, using the METAL software ⁵⁵. We also analyzed the association between genetic variants 12 13 and fracture risk, adjusting for sex, age, weight, and the first 5 principal components 14 using the PLINK software. The lead SNP of novel loci with P-value from sex-15 stratified GWASs less than 0.05 were considered to be replicated.

16

17 Identification of statistical independence and novel loci

18 The conditional independent signals for each BMD trait (between-sex meta-analysis) 19 were defined using the conditional and joint (COJO; gcta --cojo-slct) analysis⁵⁶. 20 10,000 randomly selected unrelated white British individuals from the UK Biobank 21 were used as linkage disequilibrium (LD) references. The conditional independent 22 SNV for each signal was defined as the SNV with both *P*-value for original GWAS and *P*-value for COJO joint analyses less than 5×10^{-8} . Among these independent 23 24 signals, the association was classified into the "novel" signal if all SNPs within one 25 signal (conditional independent SNV \pm 250 kb) have not been reported to be significantly associated with BMD ($P < 1 \times 10^{-6}$) in previous BMD GWASs ^{8,10,57}. 26 27 Across 11 BMD traits, the identified conditional independent significant SNVs were 28 merged into one locus if they were closely located to each other (<500 kb), leaving

the SNP with the smallest *P*-value as the lead SNP. The pleiotropic genomic locus
 was defined as a genomic locus containing multiple conditional independent signals
 for different BMD traits.

4

5 Variant annotation

We then used the ANNOVAR software ⁵⁸, and Functional Mapping and Annotation 6 of Genome-wide Association Studies (FUMA, <u>https://fuma.ctglab.nl/</u>)⁵⁹, as well as 7 8 Online Mendelian Inheritance in Man database (OMIM, http://omim.org/)⁶⁰, to 9 obtain functional annotation for conditional independent significant SNVs. 10 Specifically, these SNVs were first physically annotated using ANNOVAR software. 11 Based on the FUMA website, we further obtained the eQTL and chromatin 12 interaction annotation results. We selected eQTL datasets from eQTLGen 13 Consortium and five tissue types (i.e., artery tibial, whole blood, and muscle-skeletal) 14 based on the Genotype-Tissue Expression project (GTEx v8), and long-range 15 interactions (Hi-C) dataset from GSE87112 (Mesenchymal stem cell). Additionally, 16 we performed the gene map search in OMIM dataset using '(OSTEOPOROSIS OR 17 "bone fragility" OR "fragile bones" OR "bone mineral density")' to obtain gene list 18 for BMD phenotype. For each physical annotated genes, we collected corresponding 19 evidence codes from the above datasets (p for physical annotation; e for eQTL 20 annotation; h for HiC annotation; o for OMIM results).

21

22 Integrating polygenic risk score with clinical risk score for risk stratification of

23 fracture

24 Training, validation, and test datasets

We evaluated the potential clinical utility of polygenic risk scores (PRSs) for fracture incidence combined with traditional clinical risk factors. Here, two training datasets were set in the analyses for DXA-derived BMD (training dataset 1) and heel BMD/fracture (training dataset 2), respectively (**Figure 3A**). The training dataset 1

1 was derived from the aforementioned DXA-derived BMD GWAS. Additionally, all 2 fracture cases (N=35,192) and controls (N=317,599) from the UK biobank were 3 randomly divided into three distinct datasets: training dataset 2 (N=171,459 for 4 controls, N=19,363 for cases), validation (N=73,070 for controls, N=7914 for cases), 5 and test (N=73,070 for controls, N=7915 for cases). These divisions were conducted 6 according to a ratio of 2:1:1. Following this, both heel BMD GWAS and fracture 7 GWAS analyses were performed utilizing the aforementioned GWAS pipeline in 8 training dataset 2 (Figure 3A).

9

10 Generation of polygenic risk scores (PRSs)

11 Based on GWAS summary statistics from 13 traits (i.e., 11 DXA-derived BMD 12 traits, heel BMD and fracture) in training datasets, we then used the PRSice 2 13 software ⁶¹ to implement the clumping and threshold approach for developing PRSs 14 for fracture in the validation dataset (Figure 3A). The best predictive PRSs were 15 assessed for transferability and predictivity through the *P*-values and Nagelkerke R^2 in logistic model implemented in PRSice 2 software ⁶¹, which corrected for age, sex, 16 17 weight and population stratification (first five principal components). After 18 obtaining the P-values threshold for the best predictive PRS from the validation 19 dataset, we calculated the corresponding PRS for each participant in the test dataset 20 (Figure 3A).

21

22 Generation of metaPRS

To generate a combined PRS (i.e., metaPRS), we first removed the 4,248 participants with fracture history at the baseline to generate a validation cohort dataset (N=72,648 controls; N=4,088 cases) (**Figure 3A**). Based on this validation cohort dataset, we included all 13 PRSs and conducted stepwise Cox regression in the validation cohort dataset, which could automatically select a reduced number of predictor variables for building the best-performing Cox regression model.

Accordingly, we computed the metaPRS by summation of single PRS (which were
 contained in the best-performing model), weighted by beta value from stepwise Cox
 regression.

4

5 *Prediction fracture risk*

6 In this analysis, based on test datasets, we further removed the participants with 7 fracture history at the baseline, leaving 76,613 participants as the test cohort datasets 8 for fracture (N=72,629 controls; N=3,984 cases) (Figure 3A). We first generated a 9 basic FRAX-BMD model including clinical risk factors from FRAX tools [i.e., sex 10 (categorical: male and female), age (continuous: years), obesity (categorical: 1st, BMI ≤20; 2nd, 20<BMI≤25; 3rd, 25<BMI≤30; 4th, 30<BMI≤35; 5th, 35<BMI≤40;6th, 11 40<BMI≤45; 7th, BMI>45), current smoking (categorical: yes and no), current 12 13 alcohol consumption (categorical: yes and no), and glucocorticoids medicine use 14 (categorical: yes and no)] and heel BMD (Supplementary Table 21). Using Cox 15 regression for fracture, we obtained the predicted values based on the basic FRAX-16 BMD model in the test dataset. We then employed C-statistic as a quantitative 17 measure to evaluate the accuracy of the basic FRAX-BMD model using these 18 predicted values in the same dataset. Additionally, we quantify the variations in 19 discriminative power when integrating various PRSs into the basic FRAX-heel 20 BMD model (FRAX-heel BMD PRS model). Specifically, for each type of PRS (i.e., 21 heel BMD, 11 DXA-BMD, fracture and metaPRS), we performed a multiple Cox 22 regression for fracture adjusting for age, sex, obesity, smoking, alcohol, 23 glucocorticoids medicine use, heel BMD, and population stratification (the first five 24 principal components). Based on these predicted values, C-statistics and net 25 reclassification improvement (NRI) were used to estimate the improvement in 26 discrimination and reclassification after adding the various PRSs to the basic FRAX-27 BMD model. The C-statistics change was calculated by (C-statistics_{FRAX-heel BMD PRS} 28 model- C-statistics_{FRAX-heel} BMD model//(C-statistics_{FRAX-heel} BMD model-0.5)*100%. The

difference of C-statistics from various FRAX-heel BMD PRS models were
 estimated based on student t-test using *cindex.comp* function from "survomp" R
 package. The optimal cutoff point, which was obtained from the FRAX-BMD
 metaPRS model, was utilized to calculate NRI.

5

6 Additionally, to visualize the cumulative incidence of incident fractures across 7 polygenic risk categories (i.e., low (bottom quartile), intermediate (the second to the 8 third quartile), and high (top quartile) polygenic risk categories according to the 9 quintiles of the metaPRS), we employed the "survminer" R package in the test 10 cohorts consisting of time-to-fracture information and corresponding fracture events 11 as well as polygenic risk categories. We also utilized the 'cuminc' function to 12 calculate the cumulative incidence curves. Based on the survfit function from 13 "survomp" R, we estimated the 10-year absolute fracture risk, and then assessed the 14 interplay of metaPRS and the clinical risk score (from the basic FRAX-heel BMD 15 model) in impacting the risk of fracture.

16

17 Shared genetic basis of BMD and common chronic diseases

18 Genetic correlation and polygenic overlap

19 In this study, we first estimated the phenotypic correlation between 11 DXA-derived 20 BMD traits (i.e., arms, femur neck, total femur, head, leg, lumbar spine, pelvis, rib, 21 spine, total body and trunk BMD) using spearman correlation. We then supplied the 22 genetic correlation among them using GCTA software, considering the sample 23 overlap. Additionally, we performed linkage disequilibrium score regression 24 (LDSC) analyses ⁶², based on 1000 Genomes Project European panel, to assess the 25 genome-wide genetic correlation (rg) between DXA-BMD and 13 selected common 26 chronic diseases, including neurodegenerative diseases (Alzheimer's disease, 27 Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis)⁶³⁻⁶⁶, 28 cardiovascular diseases (stroke, intracranial aneurysm, atrial fibrillation, coronary

artery disease and heart failure) 67-71 and autoimmune diseases (rheumatoid arthritis, 1 systemic lupus erythematosus and inflammatory bowel diseases) 72-74. For BMD 2 phenotypes with statistically significant genetic correlation, we supplied the 3 4 bivariate causal mixture model (MiXeR) to quantify the polygenic overlap between BMD and selected chronic diseases beyond genetic correlations²⁹. For a pair of 5 6 phenotypes, MiXeR estimated the number of trait-influencing SNPs (i.e., SNPs with 7 effects on the disease not inducted by LD) for each trait and the number of shared trait-influencing SNPs based on a bivariate Gaussian mixture model²⁹. 8

9

10 Discovery of the shared risk loci

11 To discover the pleiotropic genetic variants, we performed conditional/conjunctional 12 false discovery rate (condFDR/conjFDR) analysis using genetic summary statistics. 13 We limited our analysis to BMD phenotypes that have evidence to support the 14 shared genetic architecture with common chronic diseases. Based on an empirical 15 Bayesian statistical framework, in the condFDR method, the association between 16 variant and secondary phenotype was used to re-ranks the test statistics and re-17 calculate the association of this variant with primary phenotype ^{75,76}. The conjFDR 18 is determined as the maximum of two condFDR values, which provides a 19 conservative estimate of the posterior probability that a genetic variant showed association with either trait ^{75,77}. In this study, the shared genetic variants were 20 21 defined as variants with conjFDR < 0.05. For these identified risk loci with shared 22 effects, we further used the "coloc" R package to determine whether the association 23 signals for DXA-derived BMD and common chronic diseases would co-localize at 24 the shared loci. After extracting genetic association estimates for variants within 25 250kb of the lead SNP, the probability of H4 that the two traits share one causal 26 variant were calculated. The loci with a probability of H4>0.5 were considered to 27 colocalize⁷⁸.

28

1 Genetic-driven prioritization of drug targets

2 The therapeutic target lists were obtained from the ChEMBL database (release 29), which curates the drug information from multiple sources (e.g., United States 3 4 Adopted Name applications, ClinicalTrials.gov, and FDA Orange Book database)⁷⁹. 5 Specifically, based on the targets search results, the proteins with values of activity 6 term \leq 100 and organisms from homo sapiens remained. Accordingly, a total of 7 3,329 unique druggable genes that encode human target proteins with ENSG ID for 8 approved drugs or clinical candidates were retained in the following analyses 9 (Supplementary Table 22).

10

11 We then conducted a series of bioinformatic analyses [i.e., summary-based 12 Mendelian randomization (SMR) and colocalization] to identify prioritized putative 13 druggable genes for BMD treatment. First, we assessed whether the potential 14 genetically regulated expression level of druggable genes were associated with DXA-BMD using SMR⁸⁰. In SMR analyses, the genetic variants were used as 15 16 instrumental variables to link the outcome (i.e., DXA-BMD) via the exposure of 17 interest (i.e., the expression level of candidate gene). And the instrumental variables 18 were extracted from the cis-eQTLs in three tissues (i.e., muscle, artery tibial, and whole-blood tissues) from GTEx version 8 projects ⁸¹ and from eQTLGen 19 consortium (whole blood)⁸². Linkage clumping was conducted based on default 20 21 protocols. For each DXA-dervied BMD phenotype, the SMR results of the 22 druggable genes were retained with false discovery rate (FDR)-corrected 23 significance (FDR-corrected P_{SMR} <0.05 and P_{HEIDI} >0.05). Among genes with SMR 24 evidence, we further assessed whether the eQTL and DXA-dervied BMD 25 association signals would co-localize at shared loci (i.e., the probability of H4). 26 Specifically, after extracting genetic association estimates of eQTL and DXA-27 dervied BMD traits with variants within 250kb of the lead SNP, colocalization 28 analyses were performed. The genes with a probability of H4>0.5 were considered

to colocalize ⁷⁸. The drug information of genes with SMR evidence was obtained
 from the GeneCards website (https://www.genecards.org), which collected
 information from DrugBank, ApexBio, DGIdb, ClinicalTrials.gov, and/or
 PharmGKB.

5

6 Acknowledgments

7 We thank the High-Performance Computing Center at Westlake University for the
8 facility support and technical assistance. This work was supported by China
9 National GeneBank (CNGB) and KingMed Diagnostics, Co., Ltd.

10

11 Funds

- 12 This work was supported by the National Natural Science Foundation of China
- 13 (#82370887), the "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- 14 (#2023C03164 and #2024SSYS0032), the Chinese National Key Technology R&D
- 15 Program, Ministry of Science and Technology (#2021YFC2501702), and the funds
- 16 from the Westlake Laboratory of Life Sciences and Biomedicine (#202208014).

17

18 Author contributions

- 19 H.-F.Z. conceptualized and designed the study. Y.Q. J.X. and P.G. conducted main
- 20 analysis. L.H., S.X., G.T., H.Y., G.L., and W.X. contributed additional analysis.
- 21 Y.Q., J.X., and C.X. drafted the manuscript. C.X., S.K., P.Z., M.Y., J.Z., X.L., J.G.,
- 22 S.G., X.Y., J.T., X.C., X.C., and M.M. contributed to the interpretation of the data.
- 23 P.W., G.L., C.Y., M.Q., Y.F., C.Y., G.C., L.X., D.K., Y.X., L.Y., F.H., C.C., and
- 24 Z.Z. contributed to reviewing and revising the content of the manuscript. All authors

25 reviewed and approved the final manuscript.

26

27 Declaration of interests

28 The authors declare no competing interests.

1

2 Data and code availability

- 3 The summary statistics of the present GWASs on 11 DXA-BMD traits and fracture
- 4 risk were deposited on the WBBC website ^{83,84}
- 5 (https://wbbc.westlake.edu.cn/downloads.html). This study does not report the
- 6 original code.

1 **Reference**

- 2 1. Zhu, X., Bai, W. & Zheng, H. Twelve years of GWAS discoveries for
 3 osteoporosis and related traits: advances, challenges and applications. *Bone*4 *Res* 9, 23 (2021).
- 5 2. Zheng, H.F., Spector, T.D. & Richards, J.B. Insights into the genetics of
 osteoporosis from recent genome-wide association studies. *Expert Rev Mol*7 *Med* 13, e28 (2011).
- 8 3. Salari, N. *et al.* The global prevalence of osteoporosis in the world: a
 9 comprehensive systematic review and meta-analysis. *J Orthop Surg Res* 16,
 10 609 (2021).
- 4. Guerri, S. *et al.* Quantitative imaging techniques for the assessment of
 osteoporosis and sarcopenia. *Quant Imaging Med Surg* 8, 60-85 (2018).
- 13 5. Mullin, B.H. *et al.* Genome-wide association study using family-based
 14 cohorts identifies the WLS and CCDC170/ESR1 loci as associated with bone
 15 mineral density. *BMC Genomics* 17, 136 (2016).
- 16 6. Zheng, H.F. *et al.* Meta-analysis of genome-wide studies identifies MEF2C
 17 SNPs associated with bone mineral density at forearm. *J Med Genet* 50, 47318 8 (2013).
- 19 7. Estrada, K. *et al.* Genome-wide meta-analysis identifies 56 bone mineral
 20 density loci and reveals 14 loci associated with risk of fracture. *Nat Genet* 44,
 21 491-501 (2012).
- 22 8. Zheng, H.F. *et al.* Whole-genome sequencing identifies EN1 as a determinant
 23 of bone density and fracture. *Nature* 526, 112-7 (2015).
- 24 9. Kemp, J.P. *et al.* Identification of 153 new loci associated with heel bone
 25 mineral density and functional involvement of GPC6 in osteoporosis. *Nat*26 *Genet* 49, 1468-1475 (2017).
- 27 10. Morris, J.A. *et al.* An atlas of genetic influences on osteoporosis in humans
 28 and mice. *Nat Genet* 51, 258-266 (2019).
- Lu, T. *et al.* Improved prediction of fracture risk leveraging a genome-wide
 polygenic risk score. *Genome Med* 13, 16 (2021).
- Lu, T., Forgetta, V., Zhou, S., Richards, J.B. & Greenwood, C.M. Identifying
 Rare Genetic Determinants for Improved Polygenic Risk Prediction of Bone
 Mineral Density and Fracture Risk. *J Bone Miner Res* (2023).
- Tuna, H. *et al.* Does quantitative tibial ultrasound predict low bone mineral
 density defined by dual energy X-ray absorptiometry? *Yonsei Med J* 49, 43642 (2008).
- Xia, J.W. *et al.* Both indirect maternal and direct fetal genetic effects reflect
 the observational relationship between higher birth weight and lower adult
 bone mass. *BMC Med* 20, 361 (2022).
- 40 15. Zhao, P. *et al.* Deciphering the complex relationship between type 2 diabetes
 41 and fracture risk with both genetic and observational evidence. *Elife*

1		12 (2024).
2	16.	He, B. et al. Depression and Osteoporosis: A Mendelian Randomization
3		Study. Calcif Tissue Int 109, 675-684 (2021).
4	17.	Nelson, M.R. et al. The support of human genetic evidence for approved
5		drug indications. Nat Genet 47, 856-60 (2015).
6	18.	Zheng, J. et al. Phenome-wide Mendelian randomization mapping the
7		influence of the plasma proteome on complex diseases. Nat Genet 52, 1122-
8		1131 (2020).
9	19.	Kanis, J.A. et al. Case finding for the management of osteoporosis with
10		FRAXassessment and intervention thresholds for the UK. Osteoporos Int
11		19 , 1395-408 (2008).
12	20.	Evangelou, E. & Ioannidis, J.P. Meta-analysis methods for genome-wide
13		association studies and beyond. Nat Rev Genet 14, 379-89 (2013).
14	21.	Lu, Y. <i>et al.</i> Classification of osteoporosis based on bone mineral densities. J
15		Bone Miner Res 16 , 901-10 (2001).
16	22.	Medina-Gomez, C. et al. Bone mineral density loci specific to the skull
1/		portray potential pleiotropic effects on craniosynostosis. <i>Commun Biol</i> 6 , 691
18	0 2	(2023).
19	23.	Kanis, J.A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX
20		and the assessment of fracture probability in men and women from the UK.
21	24	Osteoporos Int 19, 385-97 (2008).
22	24.	Bolland, M.J. <i>et al.</i> Evaluation of the FRAX and Garvan fracture risk
23 24	25	calculators in older women. J Bone Miner Res 26, 420-7 (2011).
24 25	25.	viak, M.H., Algra, A., Brandenburg, R. & Kinkel, G.J. Prevalence of
20		unruptured infractantial aneurysins, with emphasis on sex, age, comorbidity,
20		Naurol 10, 626 36 (2011)
28	26	Ruigrok VM Rinkel G I & Wiimenge C Genetics of intracranial
20	20.	appurvsms Lancat Naurol A 170 80 (2005)
30	27	Alcorta-Sevillano N Macias I Infante A & Rodriguez C I Deciphering
31	21.	the Relevance of Bone ECM Signaling <i>Colls</i> 9 (2020)
32	28	Shin YW <i>et al</i> Association of Bone Mineral Density With the Risk of
33	20.	Intracranial Aneurysm JAMA Neurol 75 179-186 (2018)
34	29.	Frei, O. <i>et al.</i> Bivariate causal mixture model quantifies polygenic overlap
35	_>.	between complex traits beyond genetic correlation <i>Nat Commun</i> 10 2417
36		(2019).
37	30.	Lopez, I., Mak, E.C., Ding, J., Hamm, H.E. & Lomasney, J.W. A novel
38		bifunctional phospholipase c that is regulated by Galpha 12 and stimulates
39		the Ras/mitogen-activated protein kinase pathway. J Biol Chem 276, 2758-65
40		(2001).
41	31.	Papaioannou, G., Mirzamohammadi, F. & Kobayashi, T. Ras signaling
42		regulates osteoprogenitor cell proliferation and bone formation. Cell Death

1		<i>Dis</i> 7 , e2405 (2016).
2	32.	Kouchi, H. et al. Manumycin A, inhibitor of ras farnesyltransferase, inhibits
3		proliferation and migration of rat vascular smooth muscle cells. Biochem
4		Biophys Res Commun 264, 915-20 (1999).
5	33.	Cao, G. et al. How vascular smooth muscle cell phenotype switching
6		contributes to vascular disease. <i>Cell Commun Signal</i> 20 , 180 (2022).
7	34.	Cheng, W. et al. Genetic Association Between Schizophrenia and Cortical
8		Brain Surface Area and Thickness. JAMA Psychiatry 78, 1020-1030 (2021).
9	35.	Reid, I.R. & Billington, E.O. Drug therapy for osteoporosis in older adults.
10		Lancet 399 , 1080-1092 (2022).
11	36.	Reay, W.R. & Cairns, M.J. Advancing the use of genome-wide association
12		studies for drug repurposing. <i>Nat Rev Genet</i> 22 , 658-671 (2021).
13	37.	Schmidt, A.F. et al. Genetic drug target validation using Mendelian
14		randomisation. <i>Nat Commun</i> 11 , 3255 (2020).
15	38.	Holmes, M.V., Richardson, T.G., Ference, B.A., Davies, N.M. & Davey
16		Smith, G. Integrating genomics with biomarkers and therapeutic targets to
17		invigorate cardiovascular drug development. Nat Rev Cardiol 18, 435-453
18		(2021).
19	39.	Stevenson, J. & medical advisory council of the British Menopause, S.
20		Prevention and treatment of osteoporosis in women. Post Reprod Health 29,
21		11-14 (2023).
22	40.	Hu, Y., Hu, F.B. & Manson, J.E. Marine Omega-3 Supplementation and
23		Cardiovascular Disease: An Updated Meta-Analysis of 13 Randomized
24		Controlled Trials Involving 127 477 Participants. J Am Heart Assoc 8,
25		e013543 (2019).
26	41.	Qian, F. et al. Omega-3 Fatty Acid Biomarkers and Incident Atrial
27		Fibrillation. J Am Coll Cardiol 82, 336-349 (2023).
28	42.	Gao, J. et al. The Effects of n-3 PUFA Supplementation on Bone Metabolism
29		Markers and Body Bone Mineral Density in Adults: A Systematic Review
30		and Meta-Analysis of RCTs. Nutrients 15(2023).
31	43.	Dou, Y., Wang, Y., Chen, Z., Yu, X. & Ma, D. Effect of n-3 polyunsaturated
32		fatty acid on bone health: A systematic review and meta-analysis of
33		randomized controlled trials. Food Sci Nutr 10, 145-154 (2022).
34	44.	Hannah, V.C., Ou, J., Luong, A., Goldstein, J.L. & Brown, M.S. Unsaturated
35		fatty acids down-regulate srebp isoforms 1a and 1c by two mechanisms in
36		HEK-293 cells. J Biol Chem 276, 4365-72 (2001).
37	45.	Hishikawa, D. et al. Hepatic Levels of DHA-Containing Phospholipids
38		Instruct SREBP1-Mediated Synthesis and Systemic Delivery of
39		Polyunsaturated Fatty Acids. iScience 23, 101495 (2020).
40	46.	Shochat, C. et al. Deletion of SREBF1, a Functional Bone-Muscle
41		Pleiotropic Gene, Alters Bone Density and Lipid Signaling in Zebrafish.
42		Endocrinology 162 (2021).

1	47.	M., K.A.M.P.G.P.D.S.C.S.E.D.P.L.X.R.T.H.H.G.L. THU0109 Lack of
2		Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to
3		Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study.
4		Ann Rheum Dis (2014).
5	48.	Tak, P.P. et al. Chemokine receptor CCR1 antagonist CCX354-C treatment
6		for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical
7		trial. Ann Rheum Dis 72, 337-44 (2013).
8	49.	Dairaghi, D.J. et al. CCR1 blockade reduces tumor burden and osteolysis in
9		vivo in a mouse model of myeloma bone disease. Blood 120, 1449-57 (2012).
10	50.	Qian, Y. et al. Observational and genetic evidence highlight the association
11		of human sleep behaviors with the incidence of fracture. Commun Biol 4,
12		1339 (2021).
13	51.	Xia, J. et al. Systemic evaluation of the relationship between psoriasis,
14		psoriatic arthritis and osteoporosis: observational and Mendelian
15		randomisation study. Ann Rheum Dis 79, 1460-1467 (2020).
16	52.	Bai, W.Y. et al. Identification of PIEZO1 polymorphisms for human bone
17		mineral density. Bone 133, 115247 (2020).
18	53.	Bycroft, C. et al. The UK Biobank resource with deep phenotyping and
19		genomic data. Nature 562, 203-209 (2018).
20	54.	Chou, W.C. et al. A combined reference panel from the 1000 Genomes and
21		UK10K projects improved rare variant imputation in European and Chinese
22		samples. Sci Rep 6, 39313 (2016).
23	55.	Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-
24		analysis of genomewide association scans. Bioinformatics 26, 2190-2191
25		(2010).
26	56.	Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS
27		summary statistics identifies additional variants influencing complex traits.
28		Nat Genet 44, 369-75, S1-3 (2012).
29	57.	Medina-Gomez, C. et al. Life-Course Genome-wide Association Study
30		Meta-analysis of Total Body BMD and Assessment of Age-Specific Effects.
31		Am J Hum Genet 102 , 88-102 (2018).
32	58.	Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
33		genetic variants from high-throughput sequencing data. Nucleic Acids Res 38,
34		e164 (2010).
35	59.	Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional
36		mapping and annotation of genetic associations with FUMA. Nat Commun 8,
37		1826 (2017).
38	60.	Amberger, J.S., Bocchini, C.A., Schiettecatte, F., Scott, A.F. & Hamosh, A.
39		OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online
40		catalog of human genes and genetic disorders. Nucleic Acids Res 43, D789-
41		98 (2015).
42	61.	Choi, S.W. & O'Reilly, P.F. PRSice-2: Polygenic Risk Score software for

1		biobank-scale data. Gigascience 8(2019).
2	62.	Bulik-Sullivan, B.K. et al. LD Score regression distinguishes confounding
3		from polygenicity in genome-wide association studies. <i>Nat Genet</i> 47 , 291-5
4	(2)	
5	63.	Jansen, I.E. <i>et al.</i> Genome-wide meta-analysis identifies new loci and
6 7		functional pathways influencing Alzheimer's disease risk. <i>Nat Genet</i> 51 , 404-
/ 0	<i>C</i> 1	413 (2019).
0	64.	Nalls, M.A. <i>et al.</i> Identification of hovel fisk loci, causal insights, and
9 10		nerhable fisk for Parkinson's disease. a meta-analysis of genome-wide
10	65	association studies. Lancet Neurol 16, 1091-1102 (2019).
11 12	05.	amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic
יב 13		architectures and neuron specific biology Nat Ganat 53 1636 1648 (2021)
14	66	International Multiple Sclerosis Genetics <i>C</i> et al Analysis of immune-
15	00.	related loci identifies 48 new susceptibility variants for multiple sclerosis
16		Nat Genet 45 1353-60 (2013)
17	67	Malik R <i>et al</i> Multiancestry genome-wide association study of 520 000
18	07.	subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nat</i>
19		Genet 50 , 524-537 (2018).
20	68.	Bakker, M.K. <i>et al.</i> Genome-wide association study of intracranial
21		aneurysms identifies 17 risk loci and genetic overlap with clinical risk
22		factors. Nat Genet 52 , 1303-1313 (2020).
23	69.	Nielsen, J.B. et al. Biobank-driven genomic discovery yields new insight
24		into atrial fibrillation biology. Nat Genet 50, 1234-1239 (2018).
25	70.	Nelson, C.P. et al. Association analyses based on false discovery rate
26		implicate new loci for coronary artery disease. Nat Genet 49, 1385-1391
27		(2017).
28	71.	Shah, S. et al. Genome-wide association and Mendelian randomisation
29		analysis provide insights into the pathogenesis of heart failure. Nat Commun
30		11 , 163 (2020).
31	72.	Okada, Y. et al. Genetics of rheumatoid arthritis contributes to biology and
32		drug discovery. Nature 506, 376-81 (2014).
33	73.	Bentham, J. et al. Genetic association analyses implicate aberrant regulation
34		of innate and adaptive immunity genes in the pathogenesis of systemic lupus
35		erythematosus. Nat Genet 47, 1457-1464 (2015).
36	74.	Liu, J.Z. et al. Association analyses identify 38 susceptibility loci for
37		inflammatory bowel disease and highlight shared genetic risk across
38		populations. Nat Genet 47, 979-986 (2015).
39	75.	Andreassen, O.A. et al. Improved detection of common variants associated
40		with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk
41		factors. Am J Hum Genet 92, 197-209 (2013).
42	76.	Schork, A.J., Wang, Y., Thompson, W.K., Dale, A.M. & Andreassen, O.A.

1		New statistical approaches exploit the polygenic architecture of									
2		schizophreniaimplications for the underlying neurobiology. Curr Opin									
3		Neurobiol 36 , 89-98 (2016).									
4	77.	Smeland, O.B. et al. Discovery of shared genomic loci using the conditional									
5		false discovery rate approach. Hum Genet 139, 85-94 (2020).									
6	78.	Zhu, Z. et al. A genome-wide cross-trait analysis from UK Biobank									
7		highlights the shared genetic architecture of asthma and allergic diseases. Nat									
8		Genet 50, 857-864 (2018).									
9	79.	Mendez, D. et al. ChEMBL: towards direct deposition of bioassay data.									
10		Nucleic Acids Res 47, D930-D940 (2019).									
11	80.	Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies									
12		predicts complex trait gene targets. Nat Genet 48, 481-7 (2016).									
13	81.	Vosa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands									
14		of genetic loci and polygenic scores that regulate blood gene expression. Nat									
15		Genet 53, 1300-1310 (2021).									
16	82.	Consortium, G.T. Human genomics. The Genotype-Tissue Expression									
17		(GTEx) pilot analysis: multitissue gene regulation in humans. Science 348,									
18		648-60 (2015).									
19	83.	Cong, P.K. et al. Genomic analyses of 10,376 individuals in the Westlake									
20		BioBank for Chinese (WBBC) pilot project. Nat Commun 13, 2939 (2022).									
21	84.	Zhu, X.W. et al. Cohort profile: the Westlake BioBank for Chinese (WBBC)									
22		pilot project. BMJ Open 11, e045564 (2021).									
23											
24											
<u> </u>											

1 **Figure legends**

- 2 3
- Figure 1 Genetic architecture of DXA-BMD at multiple skeletal sites. (A) the
- 4 skeletal sites of 11 DXA-derived BMD traits and the GWAS study design; (B) the
- 5 associated genetic loci for DXA-derived BMD and fracture;
- 6 Abbreviations: DXA, dual-energy X-ray absorptiometry; BMD, bone mineral
- 7 density; GWAS, genome-wide association study.
- 8
- 9 Figure 2 Forest plot of the genetic association estimates of lead SNPs (A: rs746100;
- 10 B: rs10840273; C: rs12916774; D: rs6013897; E: rs927059) of novel loci with
- 11 corresponding BMD traits in female GWASs and male GWASs as well as GWAS
- 12 meta-analyses of both sexes, along with the result from Mendelian randomization 13
- analyses.
- 14 Abbreviations: BMD, bone mineral density; eQTL, expression quantitative trait
- 15 locus; IVW, inverse variance weighted; GWAS, genome-wide association study;
- 16 pQTL, genotype-protein association; SMR, summary-based Mendelian
- 17 randomization.
- 18
- 19 Figure 3 PRS demonstrated marginal improvement in fracture prediction. (A) study
- 20 design; (B) Forest plot of the association of each PRS with fracture risk, adjusting
- 21 for age, sex, obesity, smoking, alcohol, glucocorticoids medicine use, heel BMD,
- 22 and population stratification (the first five principal components); (C) The fracture
- 23 predictive results of three models. The FRAX model included clinical risk factors
- 24 from FRAX tools [i.e., sex, age, obesity, current smoking, current alcohol
- 25 consumption, and glucocorticoids medicine use]. For the FRAX-heel BMD model,
- 26 heel BMD was integrated with on the FRAX model. For the FRAX-heel BMD
- 27 metaPRA model, metaPRS was integrated into the FRAX-heel BMD model; (D)
- 28 The lifetime and 10-year probability of fracture occurrence across metaPRS
- 29 categories within each clinical risk strata.
- 30 Abbreviations: PRS, polygenic risk score
- 31
- 32 Figure 4 The shared genetic architecture of head BMD and intracranial aneurysm.
- 33 (A) heatmap of genetic and phenotypic correlation between 11 DXA-derived BMD;
- 34 (B) the genetic correlations of head BMD with 13 common chronic diseases; (C)
- 35 Venn diagrams of shared variants between head BMD and intracranial aneurysm,
- 36 and unique variants per trait; (D) Shared loci between head BMD and intracranial
- 37 aneurysm. Common genetic variants jointly associated with head BMD and
- 38 intracranial aneurysm at conjFDR < 0.05 were highlighted in red. (E) Forest plot of
- 39 the genetic association estimates of four joint-associated variants with head BMD
- 40 and intracranial aneurysm.
- 41 Abbreviations: BMD, bone mineral density.
- 42

- 1 **Figure 5** Prioritization of drug targets. (A) the result of four genes with mendelian
- 2 randomization evidence. The red downward triangle indicates that genetically
- 3 predicted expression level of this gene is negatively correlated with BMD, while the
- 4 blue upward triangle indicates a positive association for BMD; (B) Forest plot of the
- 5 association of genetically predicted SREBF1, CCR1, NCOR1 and ESR1 gene
- 6 expression with BMD, based on summary-based mendelian randomization analyses;
- 7 (C) colocalization results of GWAS and eQTL within SREBF1, CCR1, NCOR1 and
- 8 ESR1 gene regions; (D) the drug development status of SREBF1, CCR1, NCOR1
- 9 and *ESR1* genes.
- 10 Abbreviations: BMD, bone mineral density; eQTL, expression quantitative trait
- 11 locus; GWAS, genome-wide association study.

		Cond	litional independent si	ignals	
Phenotype Sample size Known Novel		Novel	Total	- Heritability	
Single BMD phenotype					
Head BMD	31986	69	0	69	0.418 (0.045)
Arm BMD	31873	34	0	34	0.321 (0.039)
Femoral neck BMD	32017	36	4	40	0.257 (0.029≩
Femur total BMD	31873	41	3	44	0.319 (0.030)
Leg BMD	31873	43	1	44	0.320 (0.034
Lumbar spine BMD	30449	40	1	41	0.363 (0.034)
Pelvis BMD	31873	48	1	49	0.351 (0.036
Rib BMD	31873	22	0	22	0.298 (0.030
Spine BMD	31986	37	0	37	0.353 (0.034)
Total BMD	31986	61	0	61	0.379 (0.039)
Trunk BMD	31873	45	1	46	0.360 (0.036)
All BMD-related phenotypes	\	476 (232 unique)	11 (8 unique)	487 (240 unique)	\ X it
Fracture	352,791	8	0	8	0.048 (0.007§
	(N=35,192 for cases; N=317,599 for controls)				permis
Acorss phenotypes	\	87	5	92	\ sion

ahla 1	l the	detailed	inf	ormation	on	genome_wide	association	studies	of 11	hone	mineral	density	v sites
able	l uie	uetaneu	IIII	ormation	OII	genome-wide		studies	0111	Done	mmerai	uensity	sites.



Exposure	Outcome	Method		beta (se)	<i>P</i> -value
Conditional independent SNP: rs1039406 (9:107748958) for allele T	Lumber spine BMD				
	Male $(N = 14563)$	GWAS	HEH	0.041 (0.012)	3.75×10-4
	Female ($N = 12964$)	GWAS	H H H	0.057 (0.012)	5.70×10 ⁻⁶
	sex-combined ($N = 27527$)	GWAS	HEH	0.049 (0.009)	1.21×10 ⁻⁸
Conditional independent SNP: rs746100 (9:107749051) for allele C	Femur neck BMD				
	Male (N = 15349)	GWAS	HEH	0.043 (0.011)	1.57×10-4
	Female (N = 13633)	GWAS	HEH .	0.058 (0.012)	1.77×10 ⁻⁶
	sex-combined ($N = 28982$)	GWAS	HH	0.050 (0.008)	1.69×10-9
	Femur total BMD				
	Male $(N = 15345)$	GWAS	HHH	0.049 (0.011)	1.74×10 ⁻⁵
	Female (N = 13593)	GWAS	HeH	0.052 (0.012)	2.31×10-5
	sex-combined ($N = 28938$)	GWAS	HH	0.050 (0.008)	1.64×10-9
	Pelvis BMD				
	Male $(N = 15314)$	GWAS	HHH	0.048 (0.011)	2.03×10 ⁻⁵
	Female (N = 13639)	GWAS	HHH	0.049 (0.012)	5.67×10-5
	sex-combined ($N = 28953$)	GWAS	HH	0.049 (0.008)	4.50×10-9
	Trunk BMD				
	Male $(N = 15314)$	GWAS	HEH	0.045 (0.011)	6.22×10 ⁻⁵
	Female (N = 13639)	GWAS	H=H	0.050 (0.012)	3.74×10 ⁻⁵
	sex-combined ($N = 28953$)	GWAS	HH	0.048 (0.008)	9.35×10-9
ABCA1 gene expression in whole blood tissue from eQTLGen	Lumber spine BMD	SMR	· · · · •	→ 0.193 (0.075)	0.010
	Pelvis BMD	SMR	F =	0.185 (0.074)	0.012
	Femur neck BMD	SMR	·•	0.175 (0.073)	0.017
	Femur total BMD	SMR	·	0.176 (0.074)	0.017
		-0.	1 0 0.1 0.2 0.3	_	

A Lead SNP for loci across 11 BMD trait signals: rs746100, Canddidate gene: ABCA1

B Lead SNP for loci across 11 BMD trait signals: rs10840273, Canddidate gene: *SWAP70*

Exposure	Outcome	Method		beta (se)	<i>P</i> -value
Conditional independent SNP: rs10840273 (11:9642451) for allele T	Leg BMD		1		
	Male (N = 15326)	GWAS	HBH	0.049 (0.012)	2.59×10-5
	Female (N = 13673)	GWAS	HeH	0.050 (0.012)	4.44×10 ⁻⁵
	sex-combined ($N = 28999$)	GWAS	Here	0.050 (0.009)	4.51×10-9
SWAP70 gene expression in whole blood tissue from eQTLGen	Leg BMD	SMR	· ₽ •	0.085 (0.030)	4.00×10-3
Circulating SWAP 0 certified by peer review) is the author/funder, who has granted medRxiv a licen All rights reserved. No reuse allowed without permission	se to display the preprint in perpetuity.	IVW		0.029 (0.013)	0.027
Circulating SWAP70	Leg BMD	Weighted-median	⊢ ∎→1	0.039 (0.027)	0.025
		-0.1	0 0.1 0.2 0.3		

C Lead SNP for loci across 11 BMD trait signals: rs12916774, Canddidate gene: CHSY1

Exposure	Outcome	Method		beta (se)	<i>P</i> -value
Conditional independent SNP: rs12916774 (15:101710165) for allele A	Femur neck BMD				
	Male (N = 15236)	GWAS	HHH	0.063 (0.014)	9.72×10-6

	Female ($N = 13523$)	GWAS	⊢≡ −1	0.061 (0.015)	6.30×10 ⁻⁵
	sex-combined ($N = 28759$)	GWAS	HHH	0.062 (0.010)	2.44×10-9
Conditional independent SNP: rs11630618 (15:101710434) for allele T	Femur total BMD				
	Male ($N = 15227$)	GWAS	H=-1	0.061 (0.014)	1.04×10 ⁻⁵
	Female ($N = 13481$)	GWAS	H B -1	0.050 (0.015)	7.25×10-4
	sex-combined ($N = 28708$)	GWAS	HEH	0.056 (0.010)	3.19×10 ⁻⁸
		-0.1	1 0 0.1 0.2 0.3	 }	
	Male (N = 15227) Female (N = 13481) sex-combined (N = 28708)	GWAS GWAS GWAS -0.1		0.061 (0.014) 0.050 (0.015) 0.056 (0.010)	1.04×10 ⁻⁵ 7.25×10 ⁻⁴ 3.19×10 ⁻⁸

D Lead SNP for loci across 11 BMD trait signals: rs6013897, Canddidate gene: *CYP24A1*

Exposure	Outcome	Method		beta (se)	<i>P</i> -value
Conditional independent SNP: rs35194449 (20:52742047) for allele C	Femur total BMD				
	Male (N = 15632)	GWAS	⊢ ∎1	0.069 (0.014)	1.35×10 ⁻⁶
	Female ($N = 13848$)	GWAS	⊢ ∎-+	0.061 (0.015)	5.18×10-5
	sex-combined ($N = 29480$)	GWAS	HEH	0.065 (0.010)	3.10×10 ⁻¹⁰
Conditional independent SNP: rs6013897 (20:52742479) for allele T	Femur neck BMD				
	Male ($N = 15670$)	GWAS	⊢ ∎−1	0.068 (0.014)	1.77×10 ⁻⁶
	Female ($N = 13915$)	GWAS	⊢ ∎−1	0.068 (0.015)	5.96×10-6
	sex-combined ($N = 29585$)	GWAS	HEH	0.068 (0.010)	4.56×10-11
		-0.1	0 0.1 0.2 0.3	-	

E Lead SNP for loci across 11 BMD trait signals: rs927059, Canddidate gene: PAX1

Exposure	Outcome	Method		beta (se)	<i>P</i> -value
Conditional independent SNP: rs927059 (20:21914194) for allele T	Femur neck BMD				
	Male $(N = 15651)$	GWAS	HeH	0.050 (0.011)	9.07×10-6
	Female (N = 13913)	GWAS		0.042 (0.012)	4.89×10-4
	sex-combined ($N = 29564$)	GWAS	HEH	0.047 (0.008)	1.87×10 ⁻⁸
PAX1 gene expression in whole blood tissue from eQTLGen	Femur neck BMD	SMR	⊢	0.158 (0.046)	5.33×10 ⁻⁴
		-0.1	0 0.1 0.2 0.3		



lifetime probability of fracture occurrence

10-year probability of fracture occurrence

D

B

A





A: Medelian randomization evidence

C: Colocalization evidence

D: Drug development status

Status

Approved

Approved

Approved



D
D

Exposure	Outcome			beta(SE)	<i>P</i> -value for SMR	<i>P</i> -value for HEIDI test
SREBF1 expression	Head BMD			-0.157 (0.036)	1.27×10-5	0.293
SREBF1 expression	Total BMD	■		-0.131 (0.036)	2.57×10-4	0.675
CCR1 expression	Head BMD	HEH		-0.079 (0.016)	1.76×10-6	0.094
CCR1 expression	Total BMD	+ = +		-0.084 (0.016)	3.16×10 ⁻⁷	0.053
NCOR1 expression	Head BMD		H	0.103 (0.026)	7.99×10 ⁻⁵	0.158
NCOR1 expression	Total BMD		⊢∎⊣	0.109 (0.026)	3.01×10 ⁻⁵	0.458
ESR1 expression	Head BMD	⊢∎↓		-0.296 (0.070)	2.40×10-5	0.356
ESR1 expression	Leg BMD	⊢−−−−		-0.586 (0.079)	9.13×10 ⁻¹⁴	0.078
ESR1 expression	Pelvis BMD	⊢■ (-0.556 (0.078)	7.08×10 ⁻¹³	0.052
ESR1 expression	Rib BMD	⊢		-0.661 (0.081)	4.94×10 ⁻¹⁶	0.150
ESR1 expression	Spine BMD	⊢■ 1		-0.686 (0.082)	8.98×10 ⁻¹⁷	0.095
ESR1 expression	Total BMD	⊢		-0.638 (0.081)	2.34×10 ⁻¹⁵	0.060
ESR1 expression	Trunk BMD	⊢		-0.674 (0.082)	1.93×10 ⁻¹⁶	0.056
ESR1 expression	Femur total BMD	⊢■ ↓		-0.457 (0.074)	7.53×10 ⁻¹⁰	0.108
ESR1 expression	Femur neck BMD	⊢⊨		-0.405 (0.073)	2.55×10 ⁻⁸	0.200
		-0.8 -0.6 -0.4 -0.2 0	0.2			